This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“Sensyne has made significant commercial and technological progress in the past 12 months, despite a number of challenges and the dramatic changes triggered by COVID-19. I am particularly proud of how the Company has developed solutions to some of the challenges that have arisen during the course of the pandemic. Sensyne’s achievements over the past year highlight the dedication and proficiency of our employees who are committed to supporting the Company’s mission to improve patient care and accelerate pharmaceutical research.
Recent developments have underlined the growth potential that our model can deliver as healthcare moves towards wider adoption of Clinical AI and remote patient monitoring. We look forward to the future with confidence.”
Lord Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will present the full-year results for analysts and investors today at 14:00 BST. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications. A short scientific presentation will also take place after the results presentation Q&A.
A replay of today's webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health's website after the event at https://www.sensynehealth.com/investors/investor-hub.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“Sensyne has made significant commercial and technological progress in the past 12 months, despite a number of challenges and the dramatic changes triggered by COVID-19. I am particularly proud of how the Company has developed solutions to some of the challenges that have arisen during the course of the pandemic. Sensyne’s achievements over the past year highlight the dedication and proficiency of our employees who are committed to supporting the Company’s mission to improve patient care and accelerate pharmaceutical research.
Recent developments have underlined the growth potential that our model can deliver as healthcare moves towards wider adoption of Clinical AI and remote patient monitoring. We look forward to the future with confidence.”
Lord Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will present the full-year results for analysts and investors today at 14:00 BST. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications. A short scientific presentation will also take place after the results presentation Q&A.
A replay of today's webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health's website after the event at https://www.sensynehealth.com/investors/investor-hub.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“Sensyne has made significant commercial and technological progress in the past 12 months, despite a number of challenges and the dramatic changes triggered by COVID-19. I am particularly proud of how the Company has developed solutions to some of the challenges that have arisen during the course of the pandemic. Sensyne’s achievements over the past year highlight the dedication and proficiency of our employees who are committed to supporting the Company’s mission to improve patient care and accelerate pharmaceutical research.
Recent developments have underlined the growth potential that our model can deliver as healthcare moves towards wider adoption of Clinical AI and remote patient monitoring. We look forward to the future with confidence.”
Lord Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will present the full-year results for analysts and investors today at 14:00 BST. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications. A short scientific presentation will also take place after the results presentation Q&A.
A replay of today's webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health's website after the event at https://www.sensynehealth.com/investors/investor-hub.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“Sensyne has made significant commercial and technological progress in the past 12 months, despite a number of challenges and the dramatic changes triggered by COVID-19. I am particularly proud of how the Company has developed solutions to some of the challenges that have arisen during the course of the pandemic. Sensyne’s achievements over the past year highlight the dedication and proficiency of our employees who are committed to supporting the Company’s mission to improve patient care and accelerate pharmaceutical research.
Recent developments have underlined the growth potential that our model can deliver as healthcare moves towards wider adoption of Clinical AI and remote patient monitoring. We look forward to the future with confidence.”
Lord Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will present the full-year results for analysts and investors today at 14:00 BST. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications. A short scientific presentation will also take place after the results presentation Q&A.
A replay of today's webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health's website after the event at https://www.sensynehealth.com/investors/investor-hub.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
“Sensyne has made significant commercial and technological progress in the past 12 months, despite a number of challenges and the dramatic changes triggered by COVID-19. I am particularly proud of how the Company has developed solutions to some of the challenges that have arisen during the course of the pandemic. Sensyne’s achievements over the past year highlight the dedication and proficiency of our employees who are committed to supporting the Company’s mission to improve patient care and accelerate pharmaceutical research.
Recent developments have underlined the growth potential that our model can deliver as healthcare moves towards wider adoption of Clinical AI and remote patient monitoring. We look forward to the future with confidence.”
Lord Drayson, Chief Executive Officer, and Michael Norris, Interim Chief Financial Officer, will present the full-year results for analysts and investors today at 14:00 BST. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications. A short scientific presentation will also take place after the results presentation Q&A.
A replay of today's webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health's website after the event at https://www.sensynehealth.com/investors/investor-hub.